PTC299

Identification

Name
PTC299
Accession Number
DB05173
Type
Small Molecule
Groups
Investigational
Description

PTC299 is a novel, orally administered small-molecule designed to inhibit the production of vascular endothelial growth factor (VEGF) in tumors. Overexpression of VEGF plays a key role in multiple diseases including cancer and macular degeneration. PTC299 was discovered through PTC's GEMS technology by targeting the post-transcriptional processes that regulate VEGF formation, and is currently being developed for the treatment of cancer.

Synonyms
Not Available
Categories
UNII
Not Available
CAS number
Not Available
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Investigated for use/treatment in cancer/tumors (unspecified) and solid tumors.

Structured Indications
Not Available
Pharmacodynamics

PTC299 demonstrated a broad range of activity in blocking VEGF synthesis in multiple tumor types, including breast, cervical, colorectal, fibrosarcoma, gastric, lung, melanoma, neuroblastoma, ovarian, pancreatic, prostate and renal cell cancer lines. PTC299 as a monotherapy significantly reduced VEGF concentrations in tumors and plasma, reduced tumor blood vessel density, and substantially impeded tumor progression.

Mechanism of action

PTC299 was designed to inhibit VEGF production in tumors by targeting the post-transcriptional control processes that regulate VEGF formation. Because PTC299 inhibits VEGF production, its action occurs at a different point in the VEGF pathway than therapies, such as Avastin® or Sutent®. PTC299 may be active both as a single agent or when used in combination with other anti-angiogenic agents or with chemotherapy agents for the treatment of cancers.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when PTC299 is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when PTC299 is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when PTC299 is combined with 5-androstenedione.Experimental, Illicit
AbciximabPTC299 may increase the anticoagulant activities of Abciximab.Approved
AcebutololPTC299 may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when PTC299 is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when PTC299 is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolPTC299 may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with PTC299.Approved, Vet Approved
AclarubicinPTC299 may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with PTC299.Approved
AlclofenacThe risk or severity of adverse effects can be increased when PTC299 is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when PTC299 is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when PTC299 is combined with Aldosterone.Experimental, Investigational
AldoxorubicinPTC299 may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when PTC299 is combined with Alendronic acid.Approved
AliskirenPTC299 may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when PTC299 is combined with Alminoprofen.Experimental
AlprenololPTC299 may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with PTC299.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when PTC299 is combined with Amcinonide.Approved
AmikacinPTC299 may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmiloridePTC299 may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinPTC299 may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodPTC299 may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when PTC299 is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when PTC299 is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when PTC299 is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when PTC299 is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when PTC299 is combined with Anisodamine.Investigational
AnnamycinPTC299 may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with PTC299.Approved
Antithrombin III humanPTC299 may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanPTC299 may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when PTC299 is combined with Apocynin.Investigational
ApramycinPTC299 may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when PTC299 is combined with Apremilast.Approved, Investigational
ArbekacinPTC299 may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinPTC299 may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanPTC299 may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololPTC299 may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when PTC299 is combined with Atamestane.Investigational
AtenololPTC299 may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when PTC299 is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with PTC299.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with PTC299.Approved
BalsalazidePTC299 may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminPTC299 may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when PTC299 is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololPTC299 may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinPTC299 may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with PTC299.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when PTC299 is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with PTC299.Approved
BenorilateThe risk or severity of adverse effects can be increased when PTC299 is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with PTC299.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when PTC299 is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with PTC299.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when PTC299 is combined with Betamethasone.Approved, Vet Approved
BetaxololPTC299 may decrease the antihypertensive activities of Betaxolol.Approved
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with PTC299.Approved, Investigational
BevantololPTC299 may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when PTC299 is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with PTC299.Approved, Investigational
BisoprololPTC299 may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinPTC299 may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololPTC299 may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with PTC299.Approved
BucillamineThe risk or severity of adverse effects can be increased when PTC299 is combined with Bucillamine.Investigational
BucindololPTC299 may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when PTC299 is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when PTC299 is combined with Bufexamac.Experimental
BufuralolPTC299 may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when PTC299 is combined with Bumadizone.Experimental
BumetanidePTC299 may decrease the diuretic activities of Bumetanide.Approved
BupranololPTC299 may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with PTC299.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with PTC299.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with PTC299.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with PTC299.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when PTC299 is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with PTC299.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with PTC299.Approved, Vet Approved, Withdrawn
CarteololPTC299 may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolPTC299 may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with PTC299.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with PTC299.Approved, Investigational
CeliprololPTC299 may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinPTC299 may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with PTC299.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with PTC299.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with PTC299.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of PTC299 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with PTC299.Approved
CiclesonideThe risk or severity of adverse effects can be increased when PTC299 is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with PTC299.Approved
CinoxacinPTC299 may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidPTC299 may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when PTC299 is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when PTC299 is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when PTC299 is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when PTC299 is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when PTC299 is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when PTC299 is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with PTC299.Vet Approved
CloranololPTC299 may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of PTC299 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of PTC299 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when PTC299 is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when PTC299 is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when PTC299 is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when PTC299 is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with PTC299.Experimental
CyclosporinePTC299 may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilatePTC299 may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinPTC299 may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidPTC299 may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanPTC299 may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinPTC299 may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when PTC299 is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when PTC299 is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with PTC299.Experimental
DesirudinPTC299 may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when PTC299 is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when PTC299 is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when PTC299 is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when PTC299 is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when PTC299 is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when PTC299 is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when PTC299 is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with PTC299.Approved, Investigational
DextranPTC299 may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40PTC299 may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70PTC299 may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75PTC299 may increase the anticoagulant activities of Dextran 75.Approved
DibekacinPTC299 may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with PTC299.Approved, Vet Approved
DicoumarolPTC299 may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when PTC299 is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when PTC299 is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with PTC299.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when PTC299 is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when PTC299 is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with PTC299.Approved
DihydrostreptomycinPTC299 may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with PTC299.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with PTC299.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with PTC299.Approved
DoxorubicinPTC299 may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenonePTC299 may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when PTC299 is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when PTC299 is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when PTC299 is combined with E-6201.Investigational
Edetic AcidPTC299 may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanPTC299 may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with PTC299.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with PTC299.Approved
EnoxacinPTC299 may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinPTC299 may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with PTC299.Experimental
EpanololPTC299 may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when PTC299 is combined with Epirizole.Approved
EpirubicinPTC299 may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenonePTC299 may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with PTC299.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with PTC299.Approved
EquileninThe risk or severity of adverse effects can be increased when PTC299 is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when PTC299 is combined with Equilin.Approved
EsmololPTC299 may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when PTC299 is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when PTC299 is combined with Estrone sulfate.Approved
Etacrynic acidPTC299 may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with PTC299.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when PTC299 is combined with Ethenzamide.Experimental
Ethyl biscoumacetatePTC299 may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when PTC299 is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with PTC299.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when PTC299 is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with PTC299.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when PTC299 is combined with Evening primrose oil.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when PTC299 is combined with Exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when PTC299 is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when PTC299 is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with PTC299.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with PTC299.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when PTC299 is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when PTC299 is combined with Feprazone.Experimental
Ferulic acidPTC299 may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with PTC299.Approved, Investigational
FleroxacinPTC299 may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with PTC299.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when PTC299 is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when PTC299 is combined with Fludrocortisone.Approved
FluindionePTC299 may increase the anticoagulant activities of Fluindione.Investigational
FlumequinePTC299 may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when PTC299 is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when PTC299 is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when PTC299 is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when PTC299 is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when PTC299 is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when PTC299 is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when PTC299 is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when PTC299 is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when PTC299 is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when PTC299 is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with PTC299.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when PTC299 is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with PTC299.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when PTC299 is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when PTC299 is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with PTC299.Approved, Nutraceutical, Vet Approved
FondaparinuxPTC299 may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumPTC299 may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with PTC299.Experimental
FormestaneThe risk or severity of adverse effects can be increased when PTC299 is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with PTC299.Approved
FramycetinPTC299 may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemidePTC299 may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexatePTC299 may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinPTC299 may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinPTC299 may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with PTC299.Approved, Withdrawn
GemifloxacinPTC299 may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinPTC299 may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinPTC299 may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1APTC299 may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150PTC299 may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinPTC299 may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when PTC299 is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when PTC299 is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when PTC299 is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when PTC299 is combined with HE3286.Investigational
HeparinPTC299 may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when PTC299 is combined with Higenamine.Investigational
HydralazinePTC299 may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with PTC299.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when PTC299 is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with PTC299.Approved, Investigational
Hygromycin BPTC299 may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when PTC299 is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with PTC299.Approved
IbuproxamThe risk or severity of adverse effects can be increased when PTC299 is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when PTC299 is combined with Icatibant.Approved
IdarubicinPTC299 may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxPTC299 may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with PTC299.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with PTC299.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when PTC299 is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with PTC299.Approved
IndenololPTC299 may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when PTC299 is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with PTC299.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when PTC299 is combined with Indoprofen.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with PTC299.Approved, Investigational
IsepamicinPTC299 may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when PTC299 is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when PTC299 is combined with Istaroxime.Investigational
KanamycinPTC299 may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when PTC299 is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with PTC299.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with PTC299.Approved
LabetalolPTC299 may decrease the antihypertensive activities of Labetalol.Approved
LandiololPTC299 may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with PTC299.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with PTC299.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with PTC299.Approved, Investigational
LepirudinPTC299 may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanPTC299 may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololPTC299 may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinPTC299 may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with PTC299.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with PTC299.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when PTC299 is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with PTC299.Approved
LonazolacThe risk or severity of adverse effects can be increased when PTC299 is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when PTC299 is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with PTC299.Approved
LoteprednolThe risk or severity of adverse effects can be increased when PTC299 is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when PTC299 is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with PTC299.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with PTC299.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with PTC299.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with PTC299.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with PTC299.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when PTC299 is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with PTC299.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when PTC299 is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with PTC299.Approved
MelagatranPTC299 may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when PTC299 is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with PTC299.Approved, Vet Approved
MepindololPTC299 may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazinePTC299 may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with PTC299.Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with PTC299.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with PTC299.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when PTC299 is combined with Methylprednisolone.Approved, Vet Approved
MetipranololPTC299 may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with PTC299.Approved
MetoprololPTC299 may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamidePTC299 may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinPTC299 may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with PTC299.Approved
MizoribineThe risk or severity of adverse effects can be increased when PTC299 is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with PTC299.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when PTC299 is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when PTC299 is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with PTC299.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with PTC299.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with PTC299.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with PTC299.Approved
NadololPTC299 may decrease the antihypertensive activities of Nadolol.Approved
NadroparinPTC299 may increase the anticoagulant activities of Nadroparin.Approved
NafamostatPTC299 may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with PTC299.Approved
Nalidixic AcidPTC299 may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with PTC299.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when PTC299 is combined with NCX 1022.Investigational
NeaminePTC299 may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololPTC299 may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinPTC299 may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinPTC299 may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with PTC299.Approved
NetilmicinPTC299 may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when PTC299 is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with PTC299.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with PTC299.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when PTC299 is combined with Nitroaspirin.Investigational
NorfloxacinPTC299 may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when PTC299 is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with PTC299.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with PTC299.Approved
OlsalazinePTC299 may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of can be d when PTC299 is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with PTC299.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when PTC299 is combined with Orgotein.Vet Approved
OtamixabanPTC299 may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with PTC299.Approved
Oxolinic acidPTC299 may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololPTC299 may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with PTC299.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when PTC299 is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when PTC299 is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when PTC299 is combined with Parecoxib.Approved
ParomomycinPTC299 may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when PTC299 is combined with Parthenolide.Investigational
PazufloxacinPTC299 may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinPTC299 may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololPTC299 may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitratePTC299 may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfatePTC299 may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with PTC299.Approved
PhenindionePTC299 may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonPTC299 may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with PTC299.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with PTC299.Approved, Investigational
PindololPTC299 may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidPTC299 may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinPTC299 may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanidePTC299 may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with PTC299.Approved, Investigational
Piromidic acidPTC299 may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with PTC299.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when PTC299 is combined with Pirprofen.Experimental
Platelet Activating FactorPTC299 may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinPTC299 may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinPTC299 may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with PTC299.Approved
PractololPTC299 may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with PTC299.Approved
PranoprofenThe risk or severity of adverse effects can be increased when PTC299 is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when PTC299 is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when PTC299 is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when PTC299 is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when PTC299 is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when PTC299 is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when PTC299 is combined with Pregnenolone.Experimental, Investigational
ProbenecidThe serum concentration of PTC299 can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when PTC299 is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when PTC299 is combined with Propacetamol.Approved, Investigational
PropranololPTC299 may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when PTC299 is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when PTC299 is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with PTC299.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with PTC299.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with PTC299.Vet Approved
Protein CPTC299 may increase the anticoagulant activities of Protein C.Approved
Protein S humanPTC299 may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydePTC299 may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinPTC299 may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PuromycinPTC299 may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with PTC299.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with PTC299.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with PTC299.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with PTC299.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with PTC299.Approved, Experimental, Investigational
ReviparinPTC299 may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinPTC299 may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when PTC299 is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when PTC299 is combined with Risedronate.Approved, Investigational
RivaroxabanPTC299 may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with PTC299.Investigational, Withdrawn
RosoxacinPTC299 may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinPTC299 may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinPTC299 may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with PTC299.Approved
SalicylamideThe risk or severity of adverse effects can be increased when PTC299 is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with PTC299.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with PTC299.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with PTC299.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with PTC299.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of PTC299.Approved
SemapimodThe risk or severity of adverse effects can be increased when PTC299 is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when PTC299 is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when PTC299 is combined with Serrapeptase.Investigational
SisomicinPTC299 may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinPTC299 may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of PTC299.Approved
SotalolPTC299 may decrease the antihypertensive activities of Sotalol.Approved
SP1049CPTC299 may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinPTC299 may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinPTC299 may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with PTC299.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with PTC299.Investigational
StreptomycinPTC299 may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinPTC299 may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with PTC299.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with PTC299.Approved
SulodexidePTC299 may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with PTC299.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with PTC299.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when PTC299 is combined with Suxibuzone.Experimental
TacrolimusPTC299 may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with PTC299.Approved
TalinololPTC299 may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with PTC299.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when PTC299 is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with PTC299.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when PTC299 is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when PTC299 is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with PTC299.Approved, Investigational
TemafloxacinPTC299 may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with PTC299.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when PTC299 is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when PTC299 is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with PTC299.Approved
TepoxalinThe risk or severity of adverse effects can be increased when PTC299 is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when PTC299 is combined with Teriflunomide.Approved
TertatololPTC299 may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with PTC299.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when PTC299 is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololPTC299 may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when PTC299 is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when PTC299 is combined with Tixocortol.Approved, Withdrawn
TobramycinPTC299 may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when PTC299 is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with PTC299.Approved
TorasemidePTC299 may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with PTC299.Approved
TranilastThe risk or severity of adverse effects can be increased when PTC299 is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with PTC299.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with PTC299.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when PTC299 is combined with Triamcinolone.Approved, Vet Approved
TriamterenePTC299 may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when PTC299 is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with PTC299.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when PTC299 is combined with Triptolide.Investigational
TrovafloxacinPTC299 may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinPTC299 may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when PTC299 is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with PTC299.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with PTC299.Investigational, Withdrawn
ValrubicinPTC299 may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with PTC299.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with PTC299.Approved
WarfarinPTC299 may increase the anticoagulant activities of Warfarin.Approved
XimelagatranPTC299 may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when PTC299 is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with PTC299.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with PTC299.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when PTC299 is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with PTC299.Withdrawn
Zoptarelin doxorubicinPTC299 may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinPTC299 may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347909999

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentMetastatic Breast Cancer (MBC)1
1SuspendedTreatmentCancer, Advanced1
2SuspendedTreatmentNeurofibromatosis 21

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on October 21, 2007 16:24 / Updated on November 06, 2017 06:45